Compare Crocs, Inc. (CROX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Crocs, Inc. trades at $131.17 (market cap $6.52B), while Vertex Pharmaceuticals Incorporated trades at $475.02 (market cap $120.89B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.5× Crocs, Inc.'s market cap, and Crocs, Inc. is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| CROX | VRTX | |
|---|---|---|
Market Cap | $6.52B | $120.89B |
Sector | Consumer Staples | Health |
52-Week High | $132.78 | $529.59 |
52-Week Low | $73.39 | $366.54 |
Enterprise Value | $8.11B | $115.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $130.46, down 1.75% on the day, with strong technical momentum indicated by bullish moving averages and a potential breakout pattern forming. The company has consistently beaten earnings estimates in recent quarters, though 2025 showed a net loss of $81.20M. Strategic partnerships with LEGO and Disney are driving brand innovation, while international growth, particularly in Asia, provides expansion opportunities.
The stock presents a mixed outlook with bullish analyst sentiment (51% buy ratings) and a $131.29 consensus price target offering modest upside. Key risks include recent profitability challenges, high debt levels, and competitive pressures in the footwear sector. Revenue stability and brand strength support long-term potential, but margin recovery remains critical for sustained growth.
Vertex Pharmaceuticals (VRTX) trades at $480.25, down 1.06% on the day, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a 35.51% net income margin and consistent earnings beats, while the recent $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio with up to $5 billion in peak sales potential.
The outlook remains positive given Wall Street's consensus buy rating and $538 price target, though integration risks from the Crinetics deal and past earnings volatility warrant caution. Revenue growth and margin strength position VRTX for upside, but investors should weigh acquisition execution against competitive and regulatory pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
